Drugs / CERE-120
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00252850 | Jun 2005 → Mar 2007 | Parkinson disease | Sangamo Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00985517 | Oct 2009 → Nov 2014 | Parkinson disease | Sangamo Therapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00400634 | Nov 2006 → Nov 2008 | Parkinson disease | Sangamo Therapeutics | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CERE-120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00400634 ↗ |
| Known as | AAV2-NTN | “CERE-120: AAV2-NTN” NCT00252850 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120)” NCT00252850 ↗ |
| Route | Other | “bilateral, stereotactic, intraputaminal injections of adeno-associated virus serotype 2-neurturin (CERE-120)” PMID 18387850 ↗ Apr 2008 |